NYSE - Nasdaq Real Time Price USD

Eli Lilly and Company (LLY)

781.10 +43.90 (+5.95%)
At close: 4:00 PM EDT
775.00 -6.10 (-0.78%)
After hours: 7:36 PM EDT
Loading Chart for LLY
DELL
  • Previous Close 737.20
  • Open 775.00
  • Bid 782.73 x 1200
  • Ask 777.00 x 1100
  • Day's Range 768.10 - 795.50
  • 52 Week Range 399.26 - 800.78
  • Volume 7,383,189
  • Avg. Volume 3,065,737
  • Market Cap (intraday) 742.643B
  • Beta (5Y Monthly) 0.37
  • PE Ratio (TTM) 134.21
  • EPS (TTM) 5.82
  • Earnings Date Apr 30, 2024
  • Forward Dividend & Yield 5.20 (0.71%)
  • Ex-Dividend Date Feb 14, 2024
  • 1y Target Est 826.94

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

www.lilly.com

43,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: LLY

Related Videos: LLY

Performance Overview: LLY

Trailing total returns as of 4/30/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

LLY
34.23%
S&P 500
5.57%

1-Year Return

LLY
98.97%
S&P 500
20.78%

3-Year Return

LLY
344.43%
S&P 500
19.57%

5-Year Return

LLY
605.34%
S&P 500
71.11%

Compare To: LLY

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: LLY

Valuation Measures

Annual
As of 4/29/2024
  • Market Cap

    700.90B

  • Enterprise Value

    723.20B

  • Trailing P/E

    127.10

  • Forward P/E

    59.17

  • PEG Ratio (5yr expected)

    1.40

  • Price/Sales (ttm)

    19.51

  • Price/Book (mrq)

    65.07

  • Enterprise Value/Revenue

    21.19

  • Enterprise Value/EBITDA

    84.41

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    15.36%

  • Return on Assets (ttm)

    11.88%

  • Return on Equity (ttm)

    48.44%

  • Revenue (ttm)

    34.12B

  • Net Income Avi to Common (ttm)

    5.24B

  • Diluted EPS (ttm)

    5.82

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.04B

  • Total Debt/Equity (mrq)

    243.63%

  • Levered Free Cash Flow (ttm)

    236.88M

Research Analysis: LLY

Analyst Price Targets

540.00 Low
826.94 Average
781.10 Current
1,000.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

Company Insights: LLY

Fair Value

781.10 Current
 

Dividend Score

0 Low
LLY
Sector Avg.
100 High
 

Hiring Score

0 Low
LLY
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
LLY
Sector Avg.
100 High
 

Research Reports: LLY

  • Analyst Report: Eli Lilly and Company

    Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

    Rating
    Price Target
     
  • The Argus Innovation Model Portfolio

    The United States economy is full of innovation. It has to be. Manufacturing industries that dominated the economy decades ago - textiles, televisions, even automobiles to a large degree - have moved overseas, where labor and materials costs are lower. Yet the U.S. economy, even during the pandemic and the current period of high inflation, has expanded to record levels. If U.S. corporations weren't innovating, creating new products (such as vaccines and AI) and services (such as Zoom calls) and moving into new markets, the domestic economy would not be growing, and capital would not be flooding into the country. The current high level of the U.S. dollar relative to currencies around the world attests to the confidence that global investors have in the durable and innovative U.S. economy.

     
  • Technical Assessment: Neutral in the Intermediate-Term

    Overnight events in the Middle East notwithstanding, WTI closed yesterday at $82.05/barrel, down slightly and below its recent high on April 5 and April 12 near $88. Crude oil traced out a bearish throwback, as its breakout over the top of the bullish channel that has been in place for about four months failed miserably. Generally, failed breakouts and failed breakdowns lead to decent-sized moves in the other direction. Almost the entire rally from the high $60s was labored and failed to generate much enthusiasm among market participants.

     
  • Analyst Report: Eli Lilly and Company

    Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

    Rating
    Price Target
     

People Also Watch